Business Context and Reporting Period
Company: Cardinal Health, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: June 30, 2005
Business Overview: Cardinal Health is a leading provider of products and services supporting the health care industry, organized into four segments: Pharmaceutical Distribution and Provider Services, Medical Products and Services, Pharmaceutical Technologies and Services, and Clinical Technologies and Services. The company is currently undergoing a significant business model transition in its Pharmaceutical Distribution segment, moving from a pricing-based compensation model to a fee-for-service model.
Key Financial Metrics
| Metric | Fiscal 2005 | Fiscal 2004 | Change |
|---|---|---|---|
| Revenue | $74,910.7 million | $65,053.5 million | +15% |
| Operating Earnings | $1,762.8 million | $2,348.8 million | -25% |
| Net Earnings | $1,050.7 million | $1,474.5 million | -29% |
| Diluted EPS | $2.41 | $3.35 | -28% |
| Operating Cash Flow | $2,850.2 million | $2,624.7 million | +9% |
| Total Assets | $22,059.2 million | $21,369.1 million | +3% |
| Long-term Debt | $2,319.9 million | $2,834.7 million | -18% |
| Shareholders' Equity | $8,593.0 million | $7,976.3 million | +8% |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 15% year-over-year, driven by higher sales volume, new customers, and pharmaceutical price increases (approx. 4.9% in 2005 vs. 6.2% in 2004). The Pharmaceutical Distribution segment saw a 34% increase in "Bulk Revenue."
- Earnings Decline: Operating earnings fell 25% and Net Earnings fell 29%. This decline was primarily due to:
- Reduced vendor margins in the Pharmaceutical Distribution segment due to changes in manufacturer sales practices and the transition to fee-for-service agreements.
- Special items totaling $264.2 million (including $203.0 million in restructuring costs and $25.0 million reserved for SEC investigation settlement).
- Asset impairments of $118.0 million, compared to gains of $11.5 million in the prior year.
- Declining performance in the Pyxis products business (Clinical Technologies) due to product launch delays and competition.
- Segment Performance:
- Pharmaceutical Distribution: Operating earnings decreased 2% due to margin compression.
- Pharmaceutical Technologies: Operating earnings decreased 28% due to facility delays and regulatory issues.
- Clinical Technologies: Operating earnings decreased 19% due to Pyxis declines, partially offset by the Alaris acquisition.
Guidance, Outlook, Risks, and Contingencies
- SEC Investigation & Restatements: The company is subject to a formal SEC investigation and a U.S. Attorney inquiry regarding revenue classification and accounting practices. The company recorded a $25 million reserve for potential settlement. While the Audit Committee's internal review is substantially complete, there is a risk of additional restatements or disciplinary actions. The company has implemented significant internal control enhancements, including new CFO, CECO, and Controller appointments.
- Business Model Transition: The Pharmaceutical Distribution segment is transitioning to fee-for-service agreements to reduce earnings volatility. However, some agreements still contain inflation-based components, exposing the company to risk if pharmaceutical price inflation is lower than anticipated.
- Restructuring Program: The "One Cardinal Health" global restructuring program is underway, expected to be substantially complete by fiscal 2008. The company expects the program to improve operating earnings by approximately $190 million in fiscal 2006.
- Legal Proceedings: Significant litigation includes shareholder class actions (securities and ERISA), latex litigation (resolved with a $28.2 million charge in 2005), and patent infringement suits (e.g., ICU Medical vs. Alaris).
- Customer Concentration: CVS (21%) and Walgreens (10%) accounted for 31% of total revenue. The loss of these customers would materially impact results.
Key Facts for Investor Verification
- SEC Settlement Terms: Verify the final terms and total cost of the settlement with the SEC, as the current $25 million reserve may be insufficient.
- Fee-for-Service Transition: Monitor the progress of the transition to fee-for-service agreements in the Pharmaceutical Distribution segment and the impact on gross margins.
- Pyxis Product Recovery: Assess the recovery of the Pyxis products business following the launch of the MedStation 3000 and the resolution of installation delays.
- Restructuring Costs: Track the actual costs and savings realized from the "One Cardinal Health" restructuring program against the projected $190 million benefit for fiscal 2006.
- Internal Controls: Confirm the effectiveness of the new internal controls and governance measures in preventing future accounting irregularities.